Trial Profile

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil in Healthy Subjects Aged 9 to 13 Years in Malaysia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYD TDV (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Dengue; Human papillomavirus infections
Focus Pharmacodynamics
Sponsors Sanofi Pasteur

Most Recent Events

01 Aug 2021 Results published in the Pediatric Infectious Disease Journal
21 May 2020 Status changed from active, no longer recruiting to completed.
24 Jun 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com